PeptideStack
5.2kquestions
20kanswers
220users

Is a 95.2% result from Medutest comparable to 96.8% from Janoshik?

Asked 7 Aug 2024Modified 20 months agoViewed 25k times
27

Setup, so nobody has to ask: 95.2% · Medutest · 96.8% · Janoshik.

I suspect the honest answer is that it depends, in which case I would like to know on what.

Assume I can obtain either option without difficulty, so availability is not the deciding factor.

Under what conditions does the answer flip?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
KS
askedk_szabo45k387 Aug 2024
This is the answer I was looking for three months ago. – eoin_mcgarry 10 days ago
The arithmetic checks out. I ran the same numbers and got the same result. – deamidation_watch 9 months ago
add a comment

5 Answers

Accepted answer first, then by votes
39

Accepted answer

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Put another way, buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
UM
answered · acceptedunit_math13k185 Oct 2024
7I would add a sentence about sterility here, since it is the thing people skip. – a_lindgren 3 months ago
6The placebo-arm figure is the part everyone omits. – RP_C18 2 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
13

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

To be exact about it, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
MI
answeredmicron2236k13816 Oct 2024
5Related: the same reasoning applies to the counter-ion question. – Dr_Elias_Weiss 9 months ago
add a comment
13

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The underlying point is that sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
DB
answeredDr_Fatima_Belkacem52k13827 Oct 2024
10

Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
SB
answereds_bhattacharya42k3822 Aug 2024
8This should probably be in the site help pages rather than buried in an answer. – micron22 7 days ago
Good answer, but the confidence interval in the cited trial is wider than implied. – Dr_Rosalind_Achebe 2 months ago
add a comment
10

The relevant detail is that understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 2 Dec 2024 by tobias_maartens — corrected a unit error in the worked example

shareimprove this answerflag
TM
answeredtobias_maartens94k2587 Nov 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.